Lurbinectedin is a drug that has shown promise in the treatment of certain types of cancers. However, it is important to note that its use in combination therapy for all cancers is still being studied and is not yet fully established.

According to the information provided by DrugPatentWatch, lurbinectedin is currently approved for the treatment of metastatic small cell lung cancer (SCLC) in the United States[1]. This indicates that it has been specifically studied and approved for this particular type of cancer.

The National Cancer Institute (NCI) provides a database of ongoing clinical trials, including those involving lurbinectedin. Upon reviewing the available information, it appears that there are several clinical trials investigating the use of lurbinectedin in combination with other drugs for various types of cancers[2]. These trials include studies for ovarian cancer, endometrial cancer, and advanced solid tumors, among others. However, it is important to note that these trials are still in progress and the results are not yet available.

A study published in PubMed provides further insight into the potential use of lurbinectedin in combination therapy. The study specifically focuses on the combination of lurbinectedin with another drug called doxorubicin for the treatment of relapsed small cell lung cancer[3]. The results of this study showed promising efficacy and tolerability, suggesting that lurbinectedin in combination with doxorubicin could be a viable treatment option for this particular type of cancer.

In summary, while lurbinectedin has shown promise in the treatment of certain types of cancers, its use in combination therapy for all cancers is still being investigated. It is currently approved for the treatment of metastatic small cell lung cancer, and there are ongoing clinical trials exploring its potential use in combination with other drugs for various types of cancers. Further research is needed to determine the effectiveness and safety of lurbinectedin in combination therapy for different cancer types.

Sources:
[1] DrugPatentWatch. Lurbinectedin Tradename Information. Retrieved from: https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] National Cancer Institute. Clinical Trials Search Results for Lurbinectedin. Retrieved from: https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2022-10037
[3] PubMed. Lurbinectedin and doxorubicin combination therapy for the treatment of relapsed small cell lung cancer. Retrieved from: https://pubmed.ncbi.nlm.nih.gov/36455505/